XML 38 R20.htm IDEA: XBRL DOCUMENT
v3.21.1

STOCK OPTION PLANS | 12 Months Ended
--- | ---
Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
STOCK OPTION PLANS | (L) Stock Option Plans On August 7, 2013, our stockholders approved the Eagle Materials Inc. Amended and Restated Incentive Plan (the Plan), which increased the shares we are authorized to issue as awards by 3,000,000 (1,500,000 of which may be stock awards). Under the terms of the Plan, we may issue equity awards, including stock options, restricted stock units (RSUs), restricted stock, and stock appreciation rights to employees of the Company and members of the Board of Directors. Awards that were already outstanding prior to the approval of the Plan remained outstanding. The Compensation Committee of our Board of Directors specifies the terms for grants of equity awards under the Plan. Long-Term Compensation Plans Options In May 2020, the Compensation Committee of the Board of Directors approved the granting to certain officers and key employees an aggregate of 96,476 performance vesting stock options that would be earned only if certain performance conditions were satisfied (the Fiscal 2021 Employee Performance Stock Option Grant). The performance criterion for the Fiscal 2021 Employee Performance Stock Option Grant was based upon the achievement of certain levels of return on equity (as defined in the option agreements), ranging from 10.0% to 20.0%, for the fiscal year ending March 31, 2021. All stock options would be earned if the return on equity was 20.0% or greater, and the percentage of shares earned are reduced proportionately to approximately 66.7% if the return on equity was 10.0%. If the Company does not achieve a return on equity of at least 10.0%, all stock options granted would have been forfeited. During fiscal 2021, our adjusted return on equity was approximately 20.0%; therefore, all 96,476 options were earned. The earned stock options will vest ratably over four years, with the first fourth vesting promptly following the determination date, and the remaining options vesting on March 31, 2022 through 2024. The Compensation Committee also approved the granting of 80,396 time-vesting stock options to the same officers and key employees, which vest ratably over a four-year period (the Fiscal 2021 Employee Time-Vesting Stock Option Grant). All of our stock options have a term of 10 years from the date of grant. All stock options issued during fiscal 2021 and 2020 were valued at the grant date using the Black-Scholes option pricing model. The weighted-average assumptions used in the Black-Scholes model to value the option awards in fiscal 2021 and 2020 are as follows:
|  | 2021 |  |  | 2020 |
Dividend Yield |  |  | 0.0 | % |  |  | 1.3 | %
Expected Volatility |  |  | 37.9 | % |  |  | 31.4 | %
Risk-Free Interest Rate |  |  | 0.44 | % |  |  | 2.31 | %
Expected Life |  | 6.0 years |  |  | 6.0 years |
Stock option expense for all outstanding stock option awards was approximately $4.9 million, $4.5 million, and $3.8 million for the years ended March 31, 2021, 2020, and 2019, respectively. At March 31, 2021, there was approximately $7.0 million of unrecognized compensation cost related to outstanding stock options, which is expected to be recognized over a weighted-average period of 2.4 years. The following table shows stock option activity for the years presented:
|  | For the Years Ended March 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
|  | Number of Shares |  |  | Weighted- Average Exercise Price |  |  | Number of Shares |  |  | Weighted- Average Exercise Price |  |  | Number of Shares |  |  | Weighted- Average Exercise Price |
Outstanding Options at Beginning of Year |  |  | 1,160,091 |  |  | $ | 80.36 |  |  |  | 1,042,925 |  |  | $ | 76.88 |  |  |  | 958,136 |  |  | $ | 72.52 |
Granted |  |  | 187,121 |  |  | $ | 61.92 |  |  |  | 187,375 |  |  | $ | 91.58 |  |  |  | 125,734 |  |  | $ | 103.53 |
Exercised |  |  | (623,617 | ) |  | $ | 70.57 |  |  |  | (62,326 | ) |  | $ | 88.28 |  |  |  | (38,748 | ) |  | $ | 54.27 |
Cancelled |  |  | (15,094 | ) |  | $ | 92.51 |  |  |  | (7,883 | ) |  | $ | 102.69 |  |  |  | (2,197 | ) |  | $ | 100.88 |
Outstanding Options at End of Year |  |  | 708,501 |  |  | $ | 83.85 |  |  |  | 1,160,091 |  |  | $ | 80.36 |  |  |  | 1,042,925 |  |  | $ | 76.88 |
Options Exercisable at End of Year |  |  | 416,817 |  |  |  |  |  |  |  | 868,081 |  |  |  |  |  |  |  | 761,564 |  |  |  |  |
Weighted-Average Fair Value of Options Granted during the Year |  |  |  |  |  | $ | 22.68 |  |  |  |  |  |  | $ | 27.35 |  |  |  |  |  |  | $ | 33.11 |
The following table summarizes information about stock options outstanding at March 31, 2021:
|  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Prices |  | Number of Shares Outstanding |  |  | Weighted- Average Remaining Contractual Life |  |  | Weighted- Average Exercise Price |  |  | Number of Shares Outstanding |  |  | Weighted- Average Exercise Price |
$33.43 - $37.34 |  |  | 14,373 |  |  |  | 1.20 |  |  | $ | 34.37 |  |  |  | 14,373 |  |  | $ | 34.37 |
$59.32 - $81.56 |  |  | 260,670 |  |  |  | 7.72 |  |  | $ | 65.46 |  |  |  | 96,420 |  |  | $ | 73.32 |
$87.34 - $106.24 |  |  | 433,458 |  |  |  | 6.74 |  |  | $ | 96.55 |  |  |  | 306,024 |  |  | $ | 96.93 |
|  |  | 708,501 |  |  |  | 6.99 |  |  | $ | 83.85 |  |  |  | 416,817 |  |  | $ | 89.31 |
At March 31, 2021, the aggregate intrinsic value for outstanding and exercisable options was approximately $35.8 million and $18.8 million, respectively. The total intrinsic value of options exercised during the fiscal years ended March 31, 2021, 2020, and 2019 was approximately $26.4 million, $2.2 million and $2.1 million, respectively. Restricted Stock In May 2020, the Compensation Committee approved the granting to certain officers and key employees an aggregate of 82,722 shares of performance vesting restricted stock that would be earned only if certain performance conditions were satisfied (the Fiscal 2021 Employee Restricted Stock Performance Award). The performance criterion for the Fiscal 2020 Employee Restricted Stock Performance Award is based upon the achievement of certain levels of return on equity (as defined in the agreement), ranging from 10.0% to 20.0%, for the fiscal year ended March 31, 2021. All restricted shares would be earned if the return on equity was 20.0% or greater, and the percentage of shares earned will be reduced proportionately to approximately 66.7% if the return on equity was 10.0%. If the Company did not achieve a return on equity of at least 10.0%, all awards would have been be forfeited. During fiscal 2021, the return on equity was approximately 20.0%; therefore all 82,722 shares were earned. Restrictions on the earned shares will lapse ratably over four years, with the first fourth lapsing promptly following the determination date and the remaining restrictions lapsing on March 31, 2022 through 2024. The Compensation Committee also approved the granting of 68,936 shares of time-vesting restricted stock to the same officers and key employees, which vest ratably over four years (the Fiscal 2021 Employee Restricted Stock Time-Vesting Award). Both of the Fiscal 2021 Employee Restricted Stock Performance Award and the Fiscal 2021 Employee Restricted Stock Time-Vesting Award were valued at the closing price of the stock on the date of grant and are being expensed over a four-year period. In August 2020, we granted to members of the Board of Directors 26,064 shares of restricted stock (the Board of Directors Fiscal 2021 Restricted Stock Award), which vested six months after the grant date. The Board of Directors Fiscal 2021 Restricted Stock Awards were valued at the closing price of the stock on the date of the grant and were expensed over a six-month period. The fair value of restricted stock is estimated based on the stock price at the date of the grant. The following table summarizes the activity for nonvested restricted shares during the fiscal years ended March 31, 2021, 2020, and 2019:
|  | For the Years Ended March 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
|  | Number of Shares |  |  | Weighted- Average Grant Date Fair Value |  |  | Number of Shares |  |  | Weighted- Average Grant Date Fair Value |  |  | Number of Shares |  |  | Weighted- Average Grant Date Fair Value |
Nonvested Restricted Stock at Beginning of Year |  |  | 233,120 |  |  | $ | 75.35 |  |  |  | 300,115 |  |  | $ | 78.94 |  |  |  | 328,059 |  |  | $ | 72.52 |
Granted |  |  | 179,377 |  |  | $ | 63.83 |  |  |  | 118,292 |  |  | $ | 90.08 |  |  |  | 121,836 |  |  | $ | 105.73 |
Vested |  |  | (136,280 | ) |  | $ | 78.89 |  |  |  | (169,347 | ) |  | $ | 92.98 |  |  |  | (147,790 | ) |  | $ | 75.94 |
Cancelled |  |  | (9,127 | ) |  | $ | 71.46 |  |  |  | (15,940 | ) |  | $ | 58.64 |  |  |  | (1,990 | ) |  | $ | 100.88 |
Nonvested Restricted Stock at End of Year |  |  | 267,090 |  |  | $ | 62.56 |  |  |  | 233,120 |  |  | $ | 75.35 |  |  |  | 300,115 |  |  | $ | 78.94 |
Expense related to restricted shares was $10.4 million, $15.3 million, and $11.3 million in fiscal years ended March 31, 2021, 2020, and 2019, respectively. At March 31, 2021, there were approximately 267,000 shares with remaining restrictions, for which $12.6 million of unearned compensation will be recognized over a weighted-average period of 2.4 years. The number of shares available for future grants of stock options, restricted stock units, stock appreciation rights, and restricted stock under the Plan was 3,449,686 at March 31, 2021. Of the available shares, a total of 1,085,034 shares can be used for future restricted stock and restricted stock unit grants.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration